SCHEMBL12238024

SCHEMBL12238024

CCc1cc2c(=O)c(-c3ccc4c(c3)OCO4)coc2cc1OC(C)=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.72
NPC1 O15118 6/20 0.72
RAB9A P51151 6/20 0.72
KMT2A Q03164 6/20 0.72
HTT P42858 4/20 0.72
TP53 P04637 4/20 0.72
HSD17B10 Q99714 3/20 0.72
TSHR P16473 1/20 0.72
ALDH1A1 P00352 7/20 0.66
LMNA P02545 4/20 0.66
CYP1A2 P05177 1/20 0.63
CYP2C19 P33261 1/20 0.63
PPARG P37231 2/20 0.58
PPARD Q03181 1/20 0.58
PPARA Q07869 1/20 0.58
MAPT P10636 7/20 0.58
MEN1 O00255 4/20 0.58
GAA P10253 1/20 0.58
PRNP P04156 1/20 0.53
GABRA1 P14867 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29527731 0.93 SMN1; SMN2 (0.73) SMN1; SMN2NPC1RAB9AKMT2AHTT
SCHEMBL12238005 0.84 PPARG (0.67) SMN1; SMN2NPC1RAB9AKMT2AHTT
SCHEMBL13904700 0.80 ALDH1A1 (0.67) SMN1; SMN2NPC1RAB9AKMT2AHTT
SCHEMBL29365787 0.80 RAB9A (0.67) SMN1; SMN2NPC1RAB9AKMT2AHTT
SCHEMBL12238004 0.79 PPARG (0.64) SMN1; SMN2NPC1RAB9AKMT2AHTT
SCHEMBL10562034 0.77 PPARG (0.75) SMN1; SMN2NPC1RAB9AKMT2AHTT
SCHEMBL12941628 0.77 ADORA2A (0.62) SMN1; SMN2NPC1RAB9AKMT2AHTT
Pseudobaptogenin SCHEMBL73016 0.74 PPARG (1.00) SMN1; SMN2NPC1RAB9AKMT2ATP53
SCHEMBL4841617 0.73 MAPT (1.00) SMN1; SMN2NPC1RAB9AKMT2AHTT
SCHEMBL13904569 0.73 PPARG (0.72) SMN1; SMN2NPC1RAB9AKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9408826-B2 Isoflavone anti-viral compounds Kineta, Inc. (US) 2016-08-09 US disclosed
US-9408826-B2 Isoflavone anti-viral compounds Kineta, Inc. (US) 2016-08-09 US disclosed
US-20110262482-A1 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 US disclosed
US-20110262482-A1 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110262482-A1 ANTI-VIRAL COMPOUNDS MAVS, EIF2AK2, IRF3 SMN1; SMN2 2632/4885NPC1 1706/4885RAB9A 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.